Details and references regarding individual diseases are provided in the Supplementary Appendix. CIDP denotes chronic inflammatory demyelinating polyneuropathy, Covid-19 coronavirus disease 2019, and ...
A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SCOTTSDALE, Ariz. — A novel therapeutic approach ...
Please provide your email address to receive an email when new articles are posted on . Patients with Sjögren’s disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate ...
Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations. Farmakidis explains how ...
The immune system’s capacity to distinguish self from non-self is in large part mediated by immunoglobulins, with IgG playing a pivotal role in both protective and pathological responses.
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said its experimental immune therapy nipocalimab cleared a major clinical hurdle in systemic lupus erythematosus, delivering the first positive Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results